Article citationsMore>>

Edlin, M. (2017) Controversy Surrounds Exondys 51 Approval: What to Know. Managed Healthcare Executive.
http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/controversy-surrounds-exondys-51-approval-what-know?page=0,1

has been cited by the following article:

• TITLE: Crime against Humanity—Uncovering Two Decades of Corruption in the FDA Regarding DMD Treatment

  AUTHORS: Peter K. Law

  KEYWORDS: FDA Corruption, DMD, Duchenne Muscular Dystrophy, Exondys 51, Myoblast Transfer Therapy, Peter K. Law, Disqualification

  JOURNAL NAME: Open Journal of Regenerative Medicine, Vol.6 No.4, October 26, 2017

  ABSTRACT: The world needs to know the facts as to how the FDA “protects” the public health by assuring the safety, effectiveness, and security of human drugs and biological products for human use. Recent uproar has surfaced over the FDA’s approval process on the unproven Duchenne Muscular Dystrophy (DMD) drug, Exondys 51 (Sarepta Therapeutics, Cambridge, MA, USA), but what many people do not know are the unlawful events that occurred nearly two decades ago on a proven and promising treatment for DMD.